Table of Content

1 Vaccine Conjugate Market Overview
1.1 Vaccine Conjugate Product Overview
1.2 Vaccine Conjugate Market Segment by Type
1.2.1 Hib Vaccine
1.2.2 Meningococcal Vaccine
1.2.3 Pneumococcal Vaccine
1.2.4 Others
1.3 Global Vaccine Conjugate Market Size by Type
1.3.1 Global Vaccine Conjugate Market Size Overview by Type (2018-2029)
1.3.2 Global Vaccine Conjugate Historic Market Size Review by Type (2018-2024)
1.3.3 Global Vaccine Conjugate Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Vaccine Conjugate Sales Breakdown by Type (2018-2024)
1.4.2 Europe Vaccine Conjugate Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Vaccine Conjugate Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Vaccine Conjugate Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Vaccine Conjugate Sales Breakdown by Type (2018-2024)
2 Global Vaccine Conjugate Market Competition by Company
2.1 Global Top Players by Vaccine Conjugate Sales (2018-2024)
2.2 Global Top Players by Vaccine Conjugate Revenue (2018-2024)
2.3 Global Top Players by Vaccine Conjugate Price (2018-2024)
2.4 Global Top Manufacturers Vaccine Conjugate Manufacturing Base Distribution, Sales Area, Product Type
2.5 Vaccine Conjugate Market Competitive Situation and Trends
2.5.1 Vaccine Conjugate Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Vaccine Conjugate Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Vaccine Conjugate as of 2022)
2.7 Date of Key Manufacturers Enter into Vaccine Conjugate Market
2.8 Key Manufacturers Vaccine Conjugate Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Vaccine Conjugate Status and Outlook by Region
3.1 Global Vaccine Conjugate Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Vaccine Conjugate Historic Market Size by Region
3.2.1 Global Vaccine Conjugate Sales in Volume by Region (2018-2024)
3.2.2 Global Vaccine Conjugate Sales in Value by Region (2018-2024)
3.2.3 Global Vaccine Conjugate Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Vaccine Conjugate Forecasted Market Size by Region
3.3.1 Global Vaccine Conjugate Sales in Volume by Region (2024-2029)
3.3.2 Global Vaccine Conjugate Sales in Value by Region (2024-2029)
3.3.3 Global Vaccine Conjugate Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Vaccine Conjugate by Application
4.1 Vaccine Conjugate Market Segment by Application
4.1.1 Children
4.1.2 Adult
4.2 Global Vaccine Conjugate Market Size by Application
4.2.1 Global Vaccine Conjugate Market Size Overview by Application (2018-2029)
4.2.2 Global Vaccine Conjugate Historic Market Size Review by Application (2018-2024)
4.2.3 Global Vaccine Conjugate Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Vaccine Conjugate Sales Breakdown by Application (2018-2024)
4.3.2 Europe Vaccine Conjugate Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Vaccine Conjugate Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Vaccine Conjugate Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Vaccine Conjugate Sales Breakdown by Application (2018-2024)
5 North America Vaccine Conjugate by Country
5.1 North America Vaccine Conjugate Historic Market Size by Country
5.1.1 North America Vaccine Conjugate Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Vaccine Conjugate Sales in Volume by Country (2018-2024)
5.1.3 North America Vaccine Conjugate Sales in Value by Country (2018-2024)
5.2 North America Vaccine Conjugate Forecasted Market Size by Country
5.2.1 North America Vaccine Conjugate Sales in Volume by Country (2024-2029)
5.2.2 North America Vaccine Conjugate Sales in Value by Country (2024-2029)
6 Europe Vaccine Conjugate by Country
6.1 Europe Vaccine Conjugate Historic Market Size by Country
6.1.1 Europe Vaccine Conjugate Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Vaccine Conjugate Sales in Volume by Country (2018-2024)
6.1.3 Europe Vaccine Conjugate Sales in Value by Country (2018-2024)
6.2 Europe Vaccine Conjugate Forecasted Market Size by Country
6.2.1 Europe Vaccine Conjugate Sales in Volume by Country (2024-2029)
6.2.2 Europe Vaccine Conjugate Sales in Value by Country (2024-2029)
7 Asia-Pacific Vaccine Conjugate by Region
7.1 Asia-Pacific Vaccine Conjugate Historic Market Size by Region
7.1.1 Asia-Pacific Vaccine Conjugate Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Vaccine Conjugate Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Vaccine Conjugate Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Vaccine Conjugate Forecasted Market Size by Region
7.2.1 Asia-Pacific Vaccine Conjugate Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Vaccine Conjugate Sales in Value by Region (2024-2029)
8 Latin America Vaccine Conjugate by Country
8.1 Latin America Vaccine Conjugate Historic Market Size by Country
8.1.1 Latin America Vaccine Conjugate Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Vaccine Conjugate Sales in Volume by Country (2018-2024)
8.1.3 Latin America Vaccine Conjugate Sales in Value by Country (2018-2024)
8.2 Latin America Vaccine Conjugate Forecasted Market Size by Country
8.2.1 Latin America Vaccine Conjugate Sales in Volume by Country (2024-2029)
8.2.2 Latin America Vaccine Conjugate Sales in Value by Country (2024-2029)
9 Middle East and Africa Vaccine Conjugate by Country
9.1 Middle East and Africa Vaccine Conjugate Historic Market Size by Country
9.1.1 Middle East and Africa Vaccine Conjugate Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Vaccine Conjugate Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Vaccine Conjugate Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Vaccine Conjugate Forecasted Market Size by Country
9.2.1 Middle East and Africa Vaccine Conjugate Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Vaccine Conjugate Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Pfizer
10.1.1 Pfizer Company Information
10.1.2 Pfizer Introduction and Business Overview
10.1.3 Pfizer Vaccine Conjugate Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Pfizer Vaccine Conjugate Products Offered
10.1.5 Pfizer Recent Development
10.2 GSK
10.2.1 GSK Company Information
10.2.2 GSK Introduction and Business Overview
10.2.3 GSK Vaccine Conjugate Sales, Revenue and Gross Margin (2018-2024)
10.2.4 GSK Vaccine Conjugate Products Offered
10.2.5 GSK Recent Development
10.3 Sanofi
10.3.1 Sanofi Company Information
10.3.2 Sanofi Introduction and Business Overview
10.3.3 Sanofi Vaccine Conjugate Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Sanofi Vaccine Conjugate Products Offered
10.3.5 Sanofi Recent Development
10.4 Merck
10.4.1 Merck Company Information
10.4.2 Merck Introduction and Business Overview
10.4.3 Merck Vaccine Conjugate Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Merck Vaccine Conjugate Products Offered
10.4.5 Merck Recent Development
10.5 Walvax Biotechnology
10.5.1 Walvax Biotechnology Company Information
10.5.2 Walvax Biotechnology Introduction and Business Overview
10.5.3 Walvax Biotechnology Vaccine Conjugate Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Walvax Biotechnology Vaccine Conjugate Products Offered
10.5.5 Walvax Biotechnology Recent Development
10.6 Royal (Wuxi) Bio-Pharmaceutical
10.6.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
10.6.2 Royal (Wuxi) Bio-Pharmaceutical Introduction and Business Overview
10.6.3 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Products Offered
10.6.5 Royal (Wuxi) Bio-Pharmaceutical Recent Development
10.7 Bharat Biotech
10.7.1 Bharat Biotech Company Information
10.7.2 Bharat Biotech Introduction and Business Overview
10.7.3 Bharat Biotech Vaccine Conjugate Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Bharat Biotech Vaccine Conjugate Products Offered
10.7.5 Bharat Biotech Recent Development
10.8 Zhifei Biologic
10.8.1 Zhifei Biologic Company Information
10.8.2 Zhifei Biologic Introduction and Business Overview
10.8.3 Zhifei Biologic Vaccine Conjugate Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Zhifei Biologic Vaccine Conjugate Products Offered
10.8.5 Zhifei Biologic Recent Development
10.9 Chengdu Olymvax Biopharmaceuticals
10.9.1 Chengdu Olymvax Biopharmaceuticals Company Information
10.9.2 Chengdu Olymvax Biopharmaceuticals Introduction and Business Overview
10.9.3 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Products Offered
10.9.5 Chengdu Olymvax Biopharmaceuticals Recent Development
10.10 Beijing Minhai Biotechnology
10.10.1 Beijing Minhai Biotechnology Company Information
10.10.2 Beijing Minhai Biotechnology Introduction and Business Overview
10.10.3 Beijing Minhai Biotechnology Vaccine Conjugate Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Beijing Minhai Biotechnology Vaccine Conjugate Products Offered
10.10.5 Beijing Minhai Biotechnology Recent Development
10.11 CanSinoBIO
10.11.1 CanSinoBIO Company Information
10.11.2 CanSinoBIO Introduction and Business Overview
10.11.3 CanSinoBIO Vaccine Conjugate Sales, Revenue and Gross Margin (2018-2024)
10.11.4 CanSinoBIO Vaccine Conjugate Products Offered
10.11.5 CanSinoBIO Recent Development
10.12 Beijing Xiangrui Biological Products
10.12.1 Beijing Xiangrui Biological Products Company Information
10.12.2 Beijing Xiangrui Biological Products Introduction and Business Overview
10.12.3 Beijing Xiangrui Biological Products Vaccine Conjugate Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Beijing Xiangrui Biological Products Vaccine Conjugate Products Offered
10.12.5 Beijing Xiangrui Biological Products Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Vaccine Conjugate Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Vaccine Conjugate Industrial Chain Analysis
11.4 Vaccine Conjugate Market Dynamics
11.4.1 Vaccine Conjugate Industry Trends
11.4.2 Vaccine Conjugate Market Drivers
11.4.3 Vaccine Conjugate Market Challenges
11.4.4 Vaccine Conjugate Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Vaccine Conjugate Distributors
12.3 Vaccine Conjugate Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Hib Vaccine
Table 2. Major Company of Meningococcal Vaccine
Table 3. Major Company of Pneumococcal Vaccine
Table 4. Major Company of Others
Table 5. Global Vaccine Conjugate Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Vaccine Conjugate Sales by Type (2018-2024) & (K Doses)
Table 7. Global Vaccine Conjugate Sales Market Share in Volume by Type (2018-2024)
Table 8. Global Vaccine Conjugate Sales by Type (2018-2024) & (US& Million)
Table 9. Global Vaccine Conjugate Market Share in Value by Type (2018-2024)
Table 10. Global Vaccine Conjugate Price by Type (2018-2024) & (US$/Dose)
Table 11. Global Vaccine Conjugate Sales by Type (2024-2029) & (K Doses)
Table 12. Global Vaccine Conjugate Sales Market Share in Volume by Type (2024-2029)
Table 13. Global Vaccine Conjugate Sales by Type (2024-2029) & (US$ Million)
Table 14. Global Vaccine Conjugate Sales Market Share in Value by Type (2024-2029)
Table 15. Global Vaccine Conjugate Price by Type (2024-2029) & (US$/Dose)
Table 16. North America Vaccine Conjugate Sales by Type (2018-2024) & (K Doses)
Table 17. North America Vaccine Conjugate Sales by Type (2018-2024) & (US$ Million)
Table 18. Europe Vaccine Conjugate Sales (K Doses) by Type (2018-2024)
Table 19. Europe Vaccine Conjugate Sales by Type (2018-2024) & (US$ Million)
Table 20. Asia-Pacific Vaccine Conjugate Sales (K Doses) by Type (2018-2024)
Table 21. Asia-Pacific Vaccine Conjugate Sales by Type (2018-2024) & (US$ Million)
Table 22. Latin America Vaccine Conjugate Sales (K Doses) by Type (2018-2024)
Table 23. Latin America Vaccine Conjugate Sales by Type (2018-2024) & (US$ Million)
Table 24. Middle East and Africa Vaccine Conjugate Sales (K Doses) by Type (2018-2024)
Table 25. Middle East and Africa Vaccine Conjugate Sales by Type (2018-2024) & (US$ Million)
Table 26. Global Vaccine Conjugate Sales by Company (2018-2024) & (K Doses)
Table 27. Global Vaccine Conjugate Sales Share by Company (2018-2024)
Table 28. Global Vaccine Conjugate Revenue by Company (2018-2024) & (US$ Million)
Table 29. Global Vaccine Conjugate Revenue Share by Company (2018-2024)
Table 30. Global Market Vaccine Conjugate Price by Company (2018-2024) & (US$/Dose)
Table 31. Global Vaccine Conjugate Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 32. Global Vaccine Conjugate Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 33. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Vaccine Conjugate as of 2022)
Table 34. Date of Key Manufacturers Enter into Vaccine Conjugate Market
Table 35. Key Manufacturers Vaccine Conjugate Product Type
Table 36. Mergers & Acquisitions, Expansion Plans
Table 37. Global Vaccine Conjugate Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
Table 38. Global Vaccine Conjugate Sales by Region (2018-2024) & (K Doses)
Table 39. Global Vaccine Conjugate Sales Market Share in Volume by Region (2018-2024)
Table 40. Global Vaccine Conjugate Sales by Region (2018-2024) & (US$ Million)
Table 41. Global Vaccine Conjugate Sales Market Share in Value by Region (2018-2024)
Table 42. Global Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2024)
Table 43. Global Vaccine Conjugate Sales by Region (2024-2029) & (K Doses)
Table 44. Global Vaccine Conjugate Sales Market Share in Volume by Region (2024-2029)
Table 45. Global Vaccine Conjugate Sales by Region (2024-2029) & (US$ Million)
Table 46. Global Vaccine Conjugate Sales Market Share in Value by Region (2024-2029)
Table 47. Global Vaccine Conjugate Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2024-2029)
Table 48. Global Vaccine Conjugate Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 49. Global Vaccine Conjugate Sales by Application (2018-2024) & (K Doses)
Table 50. Global Vaccine Conjugate Sales Market Share in Volume by Application (2018-2024)
Table 51. Global Vaccine Conjugate Sales by Application (2018-2024) & (US$ Million)
Table 52. Global Vaccine Conjugate Sales Market Share in Value by Application (2018-2024)
Table 53. Global Vaccine Conjugate Price by Application (2018-2024) & (US$/Dose)
Table 54. Global Vaccine Conjugate Sales by Application (2024-2029) & (K Doses)
Table 55. Global Vaccine Conjugate Sales Market Share in Volume by Application (2024-2029)
Table 56. Global Vaccine Conjugate Sales by Application (2024-2029) & (US$ Million)
Table 57. Global Vaccine Conjugate Sales Market Share in Value by Application (2024-2029)
Table 58. Global Vaccine Conjugate Price by Application (2024-2029) & (US$/Dose)
Table 59. North America Vaccine Conjugate Sales by Application (2018-2024) (K Doses)
Table 60. North America Vaccine Conjugate Sales by Application (2018-2024) & (US$ Million)
Table 61. Europe Vaccine Conjugate Sales by Application (2018-2024) (K Doses)
Table 62. Europe Vaccine Conjugate Sales by Application (2018-2024) & (US$ Million)
Table 63. Asia-Pacific Vaccine Conjugate Sales by Application (2018-2024) (K Doses)
Table 64. Asia-Pacific Vaccine Conjugate Sales by Application (2018-2024) & (US$ Million)
Table 65. Latin America Vaccine Conjugate Sales by Application (2018-2024) (K Doses)
Table 66. Latin America Vaccine Conjugate Sales by Application (2018-2024) & (US$ Million)
Table 67. Middle East and Africa Vaccine Conjugate Sales by Application (2018-2024) (K Doses)
Table 68. Middle East and Africa Vaccine Conjugate Sales by Application (2018-2024) & (US$ Million)
Table 69. North America Vaccine Conjugate Sales by Country (2018-2024) & (K Doses)
Table 70. North America Vaccine Conjugate Sales Market Share in Volume by Country (2018-2024)
Table 71. North America Vaccine Conjugate Sales by Country (2018-2024) & (US$ Million)
Table 72. North America Vaccine Conjugate Sales Market Share in Value by Country (2018-2024)
Table 73. North America Vaccine Conjugate Sales by Country (2024-2029) & (K Doses)
Table 74. North America Vaccine Conjugate Sales Market Share in Volume by Country (2024-2029)
Table 75. North America Vaccine Conjugate Sales by Country (2024-2029) & (US$ Million)
Table 76. North America Vaccine Conjugate Sales Market Share in Value by Country (2024-2029)
Table 77. Europe Vaccine Conjugate Sales by Country (2018-2024) & (K Doses)
Table 78. Europe Vaccine Conjugate Sales Market Share in Volume by Country (2018-2024)
Table 79. Europe Vaccine Conjugate Sales by Country (2018-2024) & (US$ Million)
Table 80. Europe Vaccine Conjugate Sales Market Share in Value by Country (2018-2024)
Table 81. Europe Vaccine Conjugate Sales by Country (2024-2029) & (K Doses)
Table 82. Europe Vaccine Conjugate Sales Market Share in Volume by Country (2024-2029)
Table 83. Europe Vaccine Conjugate Sales by Country (2024-2029) & (US$ Million)
Table 84. Europe Vaccine Conjugate Sales Market Share in Value by Country (2024-2029)
Table 85. Asia-Pacific Vaccine Conjugate Sales by Region (2018-2024) & (K Doses)
Table 86. Asia-Pacific Vaccine Conjugate Sales Market Share in Volume by Region (2018-2024)
Table 87. Asia-Pacific Vaccine Conjugate Sales by Region (2018-2024) & (US$ Million)
Table 88. Asia-Pacific Vaccine Conjugate Sales Market Share in Value by Region (2018-2024)
Table 89. Asia-Pacific Vaccine Conjugate Sales by Region (2024-2029) & (K Doses)
Table 90. Asia-Pacific Vaccine Conjugate Sales Market Share in Volume by Region (2024-2029)
Table 91. Asia-Pacific Vaccine Conjugate Sales by Region (2024-2029) & (US$ Million)
Table 92. Asia-Pacific Vaccine Conjugate Sales Market Share in Value by Region (2024-2029)
Table 93. Latin America Vaccine Conjugate Sales by Country (2018-2024) & (K Doses)
Table 94. Latin America Vaccine Conjugate Sales Market Share in Volume by Country (2018-2024)
Table 95. Latin America Vaccine Conjugate Sales by Country (2018-2024) & (US$ Million)
Table 96. Latin America Vaccine Conjugate Sales Market Share in Value by Country (2018-2024)
Table 97. Latin America Vaccine Conjugate Sales by Country (2024-2029) & (K Doses)
Table 98. Latin America Vaccine Conjugate Sales Market Share in Volume by Country (2024-2029)
Table 99. Latin America Vaccine Conjugate Sales by Country (2024-2029) & (US$ Million)
Table 100. Latin America Vaccine Conjugate Sales Market Share in Value by Country (2024-2029)
Table 101. Middle East and Africa Vaccine Conjugate Sales by Country (2018-2024) & (K Doses)
Table 102. Middle East and Africa Vaccine Conjugate Sales Market Share in Volume by Country (2018-2024)
Table 103. Middle East and Africa Vaccine Conjugate Sales by Country (2018-2024) & (US$ Million)
Table 104. Middle East and Africa Vaccine Conjugate Sales Market Share in Value by Country (2018-2024)
Table 105. Middle East and Africa Vaccine Conjugate Sales by Country (2024-2029) & (K Doses)
Table 106. Middle East and Africa Vaccine Conjugate Sales Market Share in Volume by Country (2024-2029)
Table 107. Middle East and Africa Vaccine Conjugate Sales by Country (2024-2029) & (US$ Million)
Table 108. Middle East and Africa Vaccine Conjugate Sales Market Share in Value by Country (2024-2029)
Table 109. Pfizer Company Information
Table 110. Pfizer Introduction and Business Overview
Table 111. Pfizer Vaccine Conjugate Sales (K Doses), Revenue (Million USD), Price (US$/Dose) and Gross Margin (2018-2024)
Table 112. Pfizer Vaccine Conjugate Product
Table 113. Pfizer Recent Development
Table 114. GSK Company Information
Table 115. GSK Introduction and Business Overview
Table 116. GSK Vaccine Conjugate Sales (K Doses), Revenue (Million USD), Price (US$/Dose) and Gross Margin (2018-2024)
Table 117. GSK Vaccine Conjugate Product
Table 118. GSK Recent Development
Table 119. Sanofi Company Information
Table 120. Sanofi Introduction and Business Overview
Table 121. Sanofi Vaccine Conjugate Sales (K Doses), Revenue (Million USD), Price (US$/Dose) and Gross Margin (2018-2024)
Table 122. Sanofi Vaccine Conjugate Product
Table 123. Sanofi Recent Development
Table 124. Merck Company Information
Table 125. Merck Introduction and Business Overview
Table 126. Merck Vaccine Conjugate Sales (K Doses), Revenue (Million USD), Price (US$/Dose) and Gross Margin (2018-2024)
Table 127. Merck Vaccine Conjugate Product
Table 128. Merck Recent Development
Table 129. Walvax Biotechnology Company Information
Table 130. Walvax Biotechnology Introduction and Business Overview
Table 131. Walvax Biotechnology Vaccine Conjugate Sales (K Doses), Revenue (Million USD), Price (US$/Dose) and Gross Margin (2018-2024)
Table 132. Walvax Biotechnology Vaccine Conjugate Product
Table 133. Walvax Biotechnology Recent Development
Table 134. Royal (Wuxi) Bio-Pharmaceutical Company Information
Table 135. Royal (Wuxi) Bio-Pharmaceutical Introduction and Business Overview
Table 136. Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales (K Doses), Revenue (Million USD), Price (US$/Dose) and Gross Margin (2018-2024)
Table 137. Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Product
Table 138. Royal (Wuxi) Bio-Pharmaceutical Recent Development
Table 139. Bharat Biotech Company Information
Table 140. Bharat Biotech Introduction and Business Overview
Table 141. Bharat Biotech Vaccine Conjugate Sales (K Doses), Revenue (Million USD), Price (US$/Dose) and Gross Margin (2018-2024)
Table 142. Bharat Biotech Vaccine Conjugate Product
Table 143. Bharat Biotech Recent Development
Table 144. Zhifei Biologic Company Information
Table 145. Zhifei Biologic Introduction and Business Overview
Table 146. Zhifei Biologic Vaccine Conjugate Sales (K Doses), Revenue (Million USD), Price (US$/Dose) and Gross Margin (2018-2024)
Table 147. Zhifei Biologic Vaccine Conjugate Product
Table 148. Zhifei Biologic Recent Development
Table 149. Chengdu Olymvax Biopharmaceuticals Company Information
Table 150. Chengdu Olymvax Biopharmaceuticals Introduction and Business Overview
Table 151. Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Sales (K Doses), Revenue (Million USD), Price (US$/Dose) and Gross Margin (2018-2024)
Table 152. Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Product
Table 153. Chengdu Olymvax Biopharmaceuticals Recent Development
Table 154. Beijing Minhai Biotechnology Company Information
Table 155. Beijing Minhai Biotechnology Introduction and Business Overview
Table 156. Beijing Minhai Biotechnology Vaccine Conjugate Sales (K Doses), Revenue (Million USD), Price (US$/Dose) and Gross Margin (2018-2024)
Table 157. Beijing Minhai Biotechnology Vaccine Conjugate Product
Table 158. Beijing Minhai Biotechnology Recent Development
Table 159. CanSinoBIO Company Information
Table 160. CanSinoBIO Introduction and Business Overview
Table 161. CanSinoBIO Vaccine Conjugate Sales (K Doses), Revenue (Million USD), Price (US$/Dose) and Gross Margin (2018-2024)
Table 162. CanSinoBIO Vaccine Conjugate Product
Table 163. CanSinoBIO Recent Development
Table 164. Beijing Xiangrui Biological Products Company Information
Table 165. Beijing Xiangrui Biological Products Introduction and Business Overview
Table 166. Beijing Xiangrui Biological Products Vaccine Conjugate Sales (K Doses), Revenue (Million USD), Price (US$/Dose) and Gross Margin (2018-2024)
Table 167. Beijing Xiangrui Biological Products Vaccine Conjugate Product
Table 168. Beijing Xiangrui Biological Products Recent Development
Table 169. Key Raw Materials Lists
Table 170. Raw Materials Key Suppliers Lists
Table 171. Vaccine Conjugate Market Trends
Table 172. Vaccine Conjugate Market Drivers
Table 173. Vaccine Conjugate Market Challenges
Table 174. Vaccine Conjugate Market Restraints
Table 175. Vaccine Conjugate Distributors List
Table 176. Vaccine Conjugate Downstream Customers
Table 177. Research Programs/Design for This Report
Table 178. Key Data Information from Secondary Sources
Table 179. Key Data Information from Primary Sources
List of Figures
Figure 1. Vaccine Conjugate Product Picture
Figure 2. Global Vaccine Conjugate Market Size, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Vaccine Conjugate Market Size Status and Outlook (2018-2029) & (US$ Million)
Figure 4. Global Vaccine Conjugate Sales Status and Outlook (2018-2029) & (K Doses)
Figure 5. Product Picture of Hib Vaccine
Figure 6. Global Hib Vaccine Sales YoY Growth (2018-2029) & (K Doses)
Figure 7. Product Picture of Meningococcal Vaccine
Figure 8. Global Meningococcal Vaccine Sales YoY Growth (2018-2029) & (K Doses)
Figure 9. Product Picture of Pneumococcal Vaccine
Figure 10. Global Pneumococcal Vaccine Sales YoY Growth (2018-2029) & (K Doses)
Figure 11. Product Picture of Others
Figure 12. Global Others Sales YoY Growth (2018-2029) & (K Doses)
Figure 13. Global Vaccine Conjugate Sales by Type (2018-2029) & (US$ Million)
Figure 14. Global Vaccine Conjugate Sales Market Share by Type in 2022 & 2029
Figure 15. North America Vaccine Conjugate Sales Market Share in Volume by Type in 2022
Figure 16. North America Vaccine Conjugate Sales Market Share in Value by Type in 2022
Figure 17. Europe Vaccine Conjugate Sales Market Share in Volume by Type in 2022
Figure 18. Europe Vaccine Conjugate Sales Market Share in Value by Type in 2022
Figure 19. Asia-Pacific Vaccine Conjugate Sales Market Share in Volume by Type in 2022
Figure 20. Asia-Pacific Vaccine Conjugate Sales Market Share in Value by Type in 2022
Figure 21. Latin America Vaccine Conjugate Sales Market Share in Volume by Type in 2022
Figure 22. Latin America Vaccine Conjugate Sales Market Share in Value by Type in 2022
Figure 23. Middle East and Africa Vaccine Conjugate Sales Market Share in Volume by Type in 2022
Figure 24. Middle East and Africa Vaccine Conjugate Sales Market Share in Value by Type in 2022
Figure 25. The 5 and 10 Largest Manufacturers in the World: Market Share by Vaccine Conjugate Sales in 2022
Figure 26. The 5 and 10 Largest Manufacturers in the World: Market Share by Vaccine Conjugate Revenue in 2022
Figure 27. Vaccine Conjugate Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 28. Product Picture of Children
Figure 29. Global Children Sales YoY Growth (2018-2029) & (K Doses)
Figure 30. Product Picture of Adult
Figure 31. Global Adult Sales YoY Growth (2018-2029) & (K Doses)
Figure 32. Global Vaccine Conjugate Sales by Application (2018-2029) & (US$ Million)
Figure 33. Global Vaccine Conjugate Sales Market Share by Application in 2022 & 2029
Figure 34. North America Vaccine Conjugate Sales Market Share in Volume by Application in 2022
Figure 35. North America Vaccine Conjugate Sales Market Share in Value by Application in 2022
Figure 36. Europe Vaccine Conjugate Sales Market Share in Volume by Application in 2022
Figure 37. Europe Vaccine Conjugate Sales Market Share in Value by Application in 2022
Figure 38. Asia-Pacific Vaccine Conjugate Sales Market Share in Volume by Application in 2022
Figure 39. Asia-Pacific Vaccine Conjugate Sales Market Share in Value by Application in 2022
Figure 40. Latin America Vaccine Conjugate Sales Market Share in Volume by Application in 2022
Figure 41. Latin America Vaccine Conjugate Sales Market Share in Value by Application in 2022
Figure 42. Middle East and Africa Vaccine Conjugate Sales Market Share in Value by Application in 2022
Figure 43. Key Raw Materials Price
Figure 44. Vaccine Conjugate Manufacturing Cost Structure
Figure 45. Vaccine Conjugate Industrial Chain Analysis
Figure 46. Channels of Distribution
Figure 47. Distributors Profiles
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed